Business
Beyond Air® Schedules First Fiscal Quarter 2023 Financial Results Conference Call and Webcast
Call scheduled for Thursday, August 11th at 4:30 pm Eastern Time GARDEN CITY, N.Y., July 27, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a
About this update from Beyond Air, Inc.
[{"type":"text","content":"Call scheduled for Thursday, August 11th at 4:30 pm Eastern Time\nGARDEN CITY, N.Y., July 27, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that it will report financial results for its first fiscal quarter ended June 30, 2022 on Thursday, August 11, 2022. The Company’s management team is scheduled to host a conference call and webcast at 4:30 pm Eastern Time the same day. Conference Call & WebcastThursday, August 11th @ 4:30 PM ET Domestic:1-866-652-5200International:1-412-317-6060Passcode:10169266Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1560124&tp_key=09d6f2fe5d About Beyond Air, Inc.Beyond Air, Inc. is a medical device and biopharmaceutical company dedicated to harnessing the power of nitric oxide (NO) through its revolutionary NO Generator and Delivery System, LungFit®, that uses NO generated from ambient air to deliver precise amounts of NO to the lungs for the potential treatment of a variety of pulmonary diseases. The LungFit can generate up to 400 ppm of NO, for delivery either continuously or for a fixed amount of time and has the ability to either titrate dose on demand or maintain a constant dose. The Company has received FDA approval for its first system, LungFit PH for persistent pulmonary hypertension of the newborn. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as community-acquired viral pneumonia (including COVID-19), nontuberculous mycobacteria (NTM) and severe lung infections in other settings. Additionally, Beyond Cancer, an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net. Forward Looking StatementsThis press release contains “forward-looking statements” concerning inhaled nitric-oxide and the Company’s LungFit® product, including statements with regard to potential clinical and re...